Journal of Clinical Epidemiology
Volume 52, Issue 2 , Pages 167-169 , February 1999

Lipid-Lowering Medication and Risk of Cancer

  • Jørgen H. Olsen

      Affiliations

    • Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark
    • Corresponding Author InformationAddress for correspondence: Dr. J. H. Olsen, Danish Cancer Society, Institute of Cancer Epidemiology, Strandboulevarden 49, DK-2100, Copenhagen Δ, Denmark
    • ,
  • Christoffer Johansen

      Affiliations

    • Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark
    • ,
  • Henrik Toft Sørensen

      Affiliations

    • Danish Epidemiology Science Centre, University of Aarhus, Aarhus, Denmark
    • Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Joseph K. McLaughlin

      Affiliations

    • International Epidemiology Institute, Rockville, MD, USA
    • ,
  • Lene Mellemkjær

      Affiliations

    • Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark
    • ,
  • Flemming Hald Steffensen

      Affiliations

    • Department of Internal Medicine M, Aalborg Hospital, Aalborg, Denmark
    • ,
  • Joseph F. Fraumeni Jr.

      Affiliations

    • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA

,Accepted 1 September 1998.

References 

  1. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. Br Med J. 1994;308:367–372
  2. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (The Scandinavian simvastatin survival study (4S)). Lancet. 1994;344:1383–1389
  3. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  4. Jacobs DR, Muldoon MF, Råstam L. Low blood cholesterol, nonillness mortality, and other non-atherosclerotic disease mortality (A search for causes and confounders. (Invited commentary)). Am J Epidemiol. 1995;141:518–522
  5. Zureik M, Courbon D, Ducimetière P. Decline in serum total cholesterol and the risk of death from cancer. Epidemiology. 1997;8:137–143
  6. Sharp SJ, Pocock SJ. Time trends in serum cholesterol before cancer death. Epidemiology. 1997;8:132–136
  7. Vatten LJ, Foss OP. Total serum cholesterol and triglycerides and risk of breast cancer (A prospective study of 24,329 Norwegian women). Cancer Res. 1990;50:2341–2346
  8. Pekkanen J, Smith D. Should there be a moratorium on the use of cholesterol lowering drugs?. Br Med J. 1992;304:431–434
  9. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk (An epidemiologic perspective). Ann Rev Nutr. 1992;12:391–416
  10. Newman T, Huley SH. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55–60
  11. Capellá D. Descriptive tools and analysis. In:  Dukes MNG editors. Drug Utilization Studies (Methods and Uses). Copenhagen, Denmark: WHO Regional Publications; 1993;
  12. Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The Pharmaco-Epidemiologic Prescription Database of North Jutland. Int J Risk Safety Med 1997 (In press).
  13. Sørensen HT, Larsen BO. A population-based Danish data resource with possible high validity in pharmaco-epidemiological research. J Med Syst. 1994;18:33–38
  14. Jensen OM. Cancer Morbidity and Causes of Death among Danish Brewery Workers. Lyon: International Agency for Research on Cancer; 1980;
  15. Jensen OM, Storm HH, Jensen HS. Cancer registration in Denmark and the study of multiple primary cancers, 1943–1980. Natl Cancer Inst Monogr. 1985;68:245–251
  16. Bailar JC, Ederer F. Significance factors for the ratio of a Poisson variable to its expectation. Biometrics. 1964;20:639–643
  17. Cambien F, Ducimetière P. Richard JL. Total serum cholesterol and cancer mortality in middle-aged male population. Am J Epidemiol. 1980;112:388–394
  18. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361,622 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:2176–2180
  19. Jacobs D, Blackburn H, Higgins M, et al.  Report of the conference on low blood cholesterol (Mortality associations). Circulation. 1992;86:1046–1060
  20. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality (A quantitative review of primary prevention trial). Br Med J. 1990;301:309–314
  21. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J. 1994;308:373–379
  22. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313–321
  23. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  24. Olsen JH, Sørensen HT, Friis S, et al.  Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091–1094

PII: S0895-4356(98)00147-4

Journal of Clinical Epidemiology
Volume 52, Issue 2 , Pages 167-169 , February 1999

Article Tools